CryoStasis

Executive Summary

CryoStasis is a San Diego-based platform company developing advanced cryopreservation technologies for cell therapies and biologics. Founded in 2019, the company addresses a critical challenge in the cell therapy industry: maintaining viability and potency of biological samples during storage and transport. Traditional cryopreservation methods often result in significant cell loss and functional impairment, limiting the scalability and geographic reach of life-saving therapies. CryoStasis's proprietary solutions aim to improve post-thaw recovery and stability, enabling longer shelf life and reducing cold-chain logistics costs. With $8 million raised to date and a team of 50-200 employees, the company is well-positioned to serve the growing cell therapy market, which is projected to exceed $50 billion by 2030. The company is currently in the platform stage, focusing on technology validation and initial partnerships. CryoStasis has not yet disclosed specific commercial products or FDA approvals, but its core technology has broad applicability across autologous and allogeneic cell therapies, as well as biologic storage. The company's success hinges on demonstrating superior performance compared to existing cryopreservation media and equipment, and on forming strategic collaborations with cell therapy developers. Given its early stage, CryoStasis faces risks related to scalability, regulatory acceptance, and competition from established players. However, the clear unmet need and the company's innovative approach offer significant upside potential.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Top-10 Cell Therapy Developer70% success
• TBDFDA Issuance of Guidance on Cryopreservation Standards for Cell Therapies80% success
• Q4 2026Series B Funding Round Closing60% success